Silo Pharma (NASDAQ:SILO) Announces Earnings Results

Silo Pharma (NASDAQ:SILO) released its quarterly earnings results on Friday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($4.80) by $4.59, Zacks reports. Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.

Silo Pharma Stock Down 3.7%

Silo Pharma stock traded down $0.07 during midday trading on Friday, reaching $1.84. 48,855 shares of the stock traded hands, compared to its average volume of 39,794. The stock has a market cap of $2.93 million, a P/E ratio of -0.42 and a beta of 0.81. Silo Pharma has a 12 month low of $1.10 and a 12 month high of $10.43. The stock’s fifty day moving average is $1.56 and its 200-day moving average is $4.35.

Analyst Ratings Changes

Separately, Weiss Ratings cut Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Silo Pharma Company Profile

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.